Hervor Therapeutics


Launched:

2020

Management:

Frank Su

Duke Inventor(s):

Qi-Jing Li, Xiao-Fan Wang

 

 

 

Hervor Therapeutics aims to develop next-generation cancer immunotherapies that control tumor progression, convert cancers to manageable chronic diseases, and eventually lead to a cure.

Memory / Exhaustion resistant CAR-T / TCR-T therapy

Hervor Therapeutics’ unique T cell genetic engineering platform is geared to modify T cells for enhanced therapeutic potential, which includes memory T cell differentiation programs and exhaustion resistant T cell transformation programs. CAR-T and TCR-T products armed with such modifications can achieve prolonged cancer metastasis control as well as improved efficacy reach the purpose of preventing metastasis as well as improving the efficacy.